Who Generates More Revenue? ADMA Biologics, Inc. or Dynavax Technologies Corporation

Biotech Revenue Battle: ADMA vs. Dynavax

__timestampADMA Biologics, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 2014591554511032000
Thursday, January 1, 201571776334050000
Friday, January 1, 20161066103711043000
Sunday, January 1, 201722760560327000
Monday, January 1, 2018169852908198000
Tuesday, January 1, 20192934908335219000
Wednesday, January 1, 20204221978346551000
Friday, January 1, 202180942625439442000
Saturday, January 1, 2022154079692722683000
Sunday, January 1, 2023258214999232284000
Loading chart...

Unleashing insights

Revenue Race: ADMA Biologics vs. Dynavax Technologies

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, ADMA Biologics, Inc. and Dynavax Technologies Corporation have been vying for dominance. From 2014 to 2023, Dynavax has shown a remarkable growth trajectory, especially in 2021 and 2022, where its revenue surged by over 500% compared to 2014. This growth can be attributed to strategic advancements and market expansions.

Conversely, ADMA Biologics has steadily increased its revenue, peaking in 2023 with a 336% increase from its 2014 figures. This consistent growth highlights its resilience and strategic positioning in the market. While Dynavax took the lead in 2022, ADMA closed the gap in 2023, showcasing a competitive edge. As both companies continue to innovate, the revenue race remains a captivating narrative in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025